About Naropin > Benefits vs Bupivacaine > Sensory Block

Sensory Block

Choose NAROPIN® for Similar Onset, Duration, and Quality of Sensory Block1-7

When comparing NAROPIN and bupivacaine, the onset and duration of sensory block and the overall clinical efficacy of anesthesia have been reported to be comparable.1-7

REGIONAL ANESTHESIA

NAROPIN Provides Effective Sensory Block1-4


  • At equal concentrations of 0.5%, the quality of analgesia was found to be similar between NAROPIN and bupivacaine following total knee replacement3
  • Following sciatic-femoral block for total knee replacement, NAROPIN patients experienced less "at rest" and "on movement" postop pain for the first 10 hours (P<0.05) and significantly less at 7, 8, and 10 hours3
  • NAROPIN has a similar onset of sensory block in brachial plexus vs bupivacaine without compromising duration4
    • NAROPIN time to onset 13-31 minutes vs 18-58 minutes with bupivacaine4
    • Both NAROPIN and bupivacaine produced a sensory block with a mean duration of 9-11 hours4

LABOR AND DELIVERY

Chart 1: Adequate and Equivalent Anesthesia6

At equal concentrations, NAROPIN and bupivacaine produced a similar onset, extent, and duration of sensory analgesia.6




Back to Top


NAROPIN is indicated for the production of local or regional anesthesia for surgery and for acute pain management.


1. McGlade DP, Kalpokas MV, Mooney PH, et al. A comparison of 0.5% ropivacaine and 0.5% bupivacaine for axillary brachial plexus anaesthesia. Anaesth Intensive Care. 1998;26:515-520. 2. Morrison LM, Emanuelsson BM, McClure JH, et al. Efficacy and kinetics of extradural ropivacaine: comparison with bupivacaine. Br J Anaesth. 1994;72:164-169. 3. Beaulieu P, Babin D, Hemmerling T. The pharmacodynamics of ropivacaine and bupivacaine in combined sciatic and femoral nerve blocks for total knee arthroplasty. Anesth Analg. 2006;103:768-774. 4. Hickey R, Hoffman J, Ramamurthy S. A comparison of ropivacaine 0.5% and bupivacaine 0.5% for brachial plexus block. Anesthesiology. 1991;74:639-642. 5. Datta S, Camann W, Bader A, VanderBurgh L. Clinical effects and maternal and fetal plasma concentrations of epidural ropivacaine versus bupivacaine for cesarean section. Anesthesiology. 1995;82:1346-1352. 6. Griffin RP, Reynolds F. Extradural anaesthesia for caesarean section: a double-blind comparison of 0.5% ropivacaine with 0.5% bupivacaine. Br J Anaesth. 1995;74:512-516. 7. Crosby E, Sandler A, Finucane B, et al. Comparison of epidural anaesthesia with ropivacaine 0.5% and bupivacaine 0.5% for caesarian section. Can J Anaesth. 1998;45:1066-1071.


Important Safety Information

Using NAROPIN beyond recommended doses to increase motor block or duration of sensory block may negate its favorable cardiovascular advantages, in the event that an inadvertent intravascular injection occurs.
Like all amide-type local anesthetics, NAROPIN may be associated with adverse reactions. In clinical trials, side effects were mild and transient and may reflect the procedures, patient health status, and/or other medications used. Adverse events reported at a rate of ≥5%: hypotension, nausea, vomiting, bradycardia, fever, pain, postoperative complications, anemia, paresthesia, headache, pruritus, and back pain.

New Safety Information

 There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. NAROPIN is not approved for this use.

Please see Full Prescribing Information at www.naropin-us.com.

NAROPIN® and logo are registered trademarks of APP Pharmaceuticals, LLC.
®
and APP® are registered trademarks of APP Pharmaceuticals, LLC.
©2010, APP Pharmaceuticals, LLC. All Rights Reserved.